Dr. Carolyn Ng is a Partner and Managing Director at TPG Life Sciences Innovations based in San Francisco, where she leads investments into transformative companies of early to mid-stage in different therapeutic areas. She currently serves on the board of directors of Mbrace Therapeutics and Bicara Therapeutics. Prior to joining TPG in 2021, Dr. Ng was a Managing Director at Vertex Ventures HC, a global healthcare and life sciences venture fund, where she co-headed the investment team. Dr. Ng has previously served on the board of directors for other promising public and private life sciences companies including Bicycle Therapeutics PLC (NASDAQ: BCYC), Boundless Bio, Obsidian Therapeutics, 28-7 Therapeutics, Epirium Bio, Nuvaira, and a board observer to Visterra (acquired by Otsuka Pharmaceutical). Carolyn is a mentor to the Women in Bio Boardroom Ready Program. She also currently serves on the panel of the Singapore Therapeutics Development Review Panel, a funding scheme aimed at identifying high-value drug discovery and development projects from the public research community in Singapore. In 2020, she was named 20 under 40 Next Generation of Biopharma Leaders by Endpoints News, a well-established life sciences news organization. Dr. Ng holds a PhD in Cancer Molecular Biology from the National University of Singapore, where she was the recipient of the prestigious NGS, Integrative Sciences and Technology, PhD scholarship.